Alfonso De Stefano

MD, PhD. GI Medical Oncologist - Abdominal Medical Oncology Unit - INT Fondazione G. Pascale - Napoli @istitutotumori

[Alfonso De Stefano @alfdestefano]

#IMPROVE trial #INTERMITTENT or #Continuous Panitumumab Plus FOLFIRI for First-Line RAS/BRAF WT mCRC #JCO @JCO_ASCO @myESMO @OncoAlert
👌Endpoint met
👉mPFS 11.2 vs 17.5 mo
👉NO detrimental effect on OS
👉DCR 94.2% vs 91%
👉G2 skin tox 30.3% vs 17.9%

https://t.co/7TyQEvO6nr

[Alfonso De Stefano @alfdestefano]

@GillSharlene @skopetz @myESMO @OncoAlert Great discussion, kudos 🙌🏻

[Alfonso De Stefano @alfdestefano]

Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @OncoDailyGI

[Christian Rolfo @ChristianRolfo]

2025 ISLB Annual Congress, will take place in Orlando, Florida, November 1-3, 2025. This is an extraordinary gathering of scientists, clinicians, industry leaders, and innovators, all united by a shared passion for advancing liquid biopsy https://t.co/djipdLKYJX

[Davide Ciardiello @DCiardiello]

Pleased to share our latest manuscript published in @ESMO_Open 📢

@BoscoloLuca_ @Giulia_Martini1 @erikamartin3lli @MassimoDiMaio75 @ChiaraCrem1 @napolitano_ste @latiano_titty @alfdestefano @curijoey @curijoey

https://t.co/dZens2plg0

[International Society of Liquid Biopsy @isliquidbiopsy]

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸

This document underscores the importance of standardized practices in advancing the use of liquid biopsies for improved patient care.

Read more: https://t.co/rN680QpaFQ

#LiquidBiopsy #Oncology #ISLB #MedicalInnovation #CancerResearch
@ChristianRolfo @UmbertoMalapel1 @drgandara @MJOSESERRANO19 @ElJanLe

[Michael Shusterman, MD @guildsman]

14) IMPROVE Trial "Intermittent FOLFIRI plus PANITUMUMAB after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment." https://t.co/4bk3KNwgeL

[Alfonso De Stefano @alfdestefano]

@sciqst @ArndtVogel @JCO_ASCO @myESMO You highlighted the main benefits of this strategy. Actually, in about 40 Italian centers, the phase 3 IMPROVE-2 is ongoing (NCT06509126) to further support the role of intermittent treatment with FOLFIRI+Panitumumab in Left-sided pMMR, RAS/B-RAF wild-type mCRC patients 🤞

[Arndt Vogel @ArndtVogel]

Intermittent or Continuous Panitumumab + FOLFIRI for 1st line RAS and BRAF WT mCRC
@JCO_ASCO
https://t.co/z6tMwFk9dk
🔎IMPROVE Trial
👉ORR 68.1 vs 61.2%,
👉mPFS: 11.2 vs 17.5 mo
👉mOS: 36.3 vs 35.1 mo
🧐Intermittend Tx feasible, less tox
@myESMO

[Alfonso De Stefano @alfdestefano]

Many thanks to @dice_europe to share our ongoing phase III #IMPROVE-2 trial, highlighting the possible advantages of #intermittent therapy with FOLFIRI-Panitumumab in RAS BRAF wild-type #mCRC patients https://t.co/S9v5MwmD9X

[NEJM @NEJM]

An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers. Full correspondence: https://t.co/n1WtIej1xC

[Myriam Chalabi @MyriamChalabi]

Long awaited practice-changing results from ph 3 CM8HW now out in @TheLancet. Nivo/ipi sign better than nivo mono in dMMR mCRC
@sara_lonardi1 @bmsnews #GI25
https://t.co/k3MKGriWPV

[OncoDaily GI @OncoDailyGI]

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

https://t.co/CYuKJcD9aP

@tuttsakhil @alfdestefano

#Cancer #GIOnc #Crcsm #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

[Alfonso De Stefano @alfdestefano]

Thanks @oncodaily to share our results from #IMPROVE trial Continuous(C) vs Intermittent(I) ChT in #mCRC @JCO_ASCO
https://t.co/7TyQEvOEcZ
✅Endpoint met
👉mPFSot 11.2(C)vs17.5months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉⬇️skin tox
https://t.co/ilr83AsNfk

[Alfonso De Stefano @alfdestefano]

Interesting review on advances in targeting 🎯KRAS in #mCRC @OncoAlert @OncoDailyGI Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
by @DocDustyD on @JNCCN
https://t.co/gzRkna1LrL

[Alfonso De Stefano @alfdestefano]

Happy New Year to everyone!

[Alfonso De Stefano @alfdestefano]

@scserendipity1 @MedicalwatchFTW @medicalwatchBC Yes, very useful, looking for ongoing trials for our patients, mostly for tailored treatments

[Alfonso De Stefano @alfdestefano]

📢Very useful suggestions from @MedicalwatchFTW @medicalwatchBC directly forwarded to your📁📬email. You can subscribe to get a monthly update on phase 3 interventional clinical trials recruiting near you on your field of interest. Congrats and thanks for this project!

[Kate Sears @MedwatchKate]

@alfdestefano Get clinical trials near you, congress highlights and more 🙂

[Alfonso De Stefano @alfdestefano]

@todrashish Thank you, the phase III was recently launched and is actually ongoing 🤞🏻

[Kate Sears @MedwatchKate]

@SuyogCancer Want the top posts, podcasts and more?

Subscribe to our weekly newsletter and join 2,400 clinicians. Sign up free 👇👇👇